Effect of Dopaserazine Combined with Escitalopram in the Treatment of Parkinson's Disease
Objective:To analyze the clinical effect of the combination therapy of dopa-hydrazine and escitalopram in patients with Parkinson's disease.Methods:Thirty patients with Parkinson's disease admitted to Qingyuan Hospital af-filiated to Guangzhou Medical University from January 2020 to June 2024 were randomly divided into two groups,15 patients in each group.The control group was treated with dobutamine,and the observation group was treated with dobutamine combined with escitalopram.Compare the two groups:① therapeutic effect;② Adverse reactions;③Cognitive function;④ Clinical symptoms;⑤ Psychological state;⑥ Levels of inflammatory factors.Results:Compared with the control group,the effective rate in the observation group was higher,P<0.05.The incidence of adverse reac-tions between the two groups was compared,P>0.05.The levels of MoCA、UPDRS、HAMA、HAMD、IL-5 and TNF-α were compared between the two groups before intervention,P>0.05;After intervention,the MoCA score of the observation group was higher than that of the control group,and the other indexes were lower in the observation group than that of the control group,P<0.05.Conclusion:Dopamine combined with Escitalopram can improve the cognitive function,clinical symptoms and psychological state of patients with Parkinson's disease,reduce the level of in-flammatory factors and improve the therapeutic effect.
国家科技期刊平台
NSTL
万方数据
